Compound ID | 499
Class: Bacterial topoisomerase inhibitor
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | S. aureus (MRSA and quinolone resistant strains), VRE and S.pneumoniaeare susceptible to this compound |
Institute where first reported: | Quorex pharmaceuticals, USA |
Year first mentioned: | 2004 |
Highest developmental phase: | Preclinical |
Development status: | Inactive |
External links: | |
Citation: |